Full opinion text
ORDER GRANTING IN PART AND DENYING IN PART MOTION TO DISMISS Re: Dkt. No. 95 WILLIAM H. ORRICK, United States District Judge INTRODUCTION In this multidistrict antitrust litigation, plaintiffs challenge in their consolidated complaints a settlement between Endo Pharmaceuticals Inc. (“Endo”), a distributor of the brand-name drug Lidoderm, Tei-koku Seiyaku Co., its manufacturer, and Watson Pharmaceuticals, Inc. (“Watson”) a generic drug manufacturer. Plaintiffs allege that when Endo and Teikoku agreed to drop their ongoing patent litigation against Watson, they offered consideration of $96 million in free product and deferred competition with Watson’s generic product worth $170 million in exchange for Watson’s agreement to delay introduction of its generic drug. As a result of this settlement, plaintiffs were allegedly unable to purchase the cheaper generic version of Lidoderm. The central issue in defendants’ consolidated motion to dismiss is whether plaintiffs have plausibly pleaded that the settlement involved large and unjustified reverse payments that caused antitrust injury under the rule of reason analysis described in F.T.C. v. Actavis, Inc., - U.S. -, 133 S.Ct. 2223, 186 L.Ed.2d 343- (2013). For pleading purposes, plaintiffs have sufficiently alleged a violation of Section 1 of the Sherman Antitrust Act, 15 U.S.C. § 1. Plaintiffs assert a myriad of other violations of federal and state antitrust and consumer protection laws. Many of these claims require an amended pleading because of questions concerning standing or other potentially amendable defects. I am dismissing some state claims now with prejudice either because indirect purchaser antitrust claims are not available under Illinois Brick Co. v. Illinois, 431 U.S. 720, 97 S.Ct. 2061, 52 L.Ed.2d 707 (1977) and the state at issue did not pass an Illinois Brick repealer, or for reasons specific to the law of a particular state. I. PARTIES AND CLAIMS A. Defendants Endo is a Delaware corporation that markets and sells Lidoderm throughout the United States. Direct Purchaser Plaintiffs’ Consolidated Amended Complaint (“DPP Compl.”) [Dkt. No. 70] ¶ 13; End-Payor Plaintiffs’ Consolidated Amended Complaint (“EPP Compl.”) [Dkt. No. 72] ¶ 19; Government Employees Health Association First Amended Complaint (“GEHA Compl.”) [Dkt. No. 71] ¶ 23. Teikoku Seiyaku Co. is a Japanese company that manufactures Lidoderm for Endo pursuant to a Manufacturing and Supply Agreement. DPP Compl. ¶ 14; EPP Compl. ¶ 20; GEHA Compl. ¶ 24. It owns one of the patents for Lidoderm that Watson allegedly infringed. Id. Teikoku Pharma USA is a California corporation that is wholly owned by Teikoku Seiyaku Co., and is the holder of the New Drug Application for Lidoderm. DPP Compl. ¶ 15; EPP Compl. ¶21; GEHA Compl. ¶ 25. (Endo, Teikoku Seiyaku Co., and Teikoku Pharma USA will be collectively referred to as “Endo/Teikoku”). Watson Pharmaceuticals, Inc. was a Nevada corporation that marketed, produced, and distributed generic pharmaceutical products, including Lidoderm, starting in September 15, 2013. DPP Compl. ¶¶ 2, 19; EPP Compl. ¶¶ 23-24; GEHA Compl. ¶¶ 27-28. B. Plaintiffs The plaintiffs allegedly purchased generic and brand-name Lidoderm at supra-competitive prices. They are grouped into three categories based on their claims and relationship to the defendants; the direct purchaser plaintiffs (“DPPs”), entities that purchased Lidoderm directly from the defendants; the end-purchaser plaintiffs (“EPPs”), employee health and welfare benefit plans, municipal corporations, employee unions, and two individuals who purchased Lidoderm from third parties; and the Government Employees Health Association (“GEHA”), a not-for-profit corporation that provides health and dental plans to federal employees and retirees and their families that, like the EPPs, purchased Lidoderm from third parties. The DPPs bring two claims for violations of Section 1 and three claims for violations of Section 2 of the Sherman Antitrust Act, 15 U.S.C. §§ 1, 2. See DPP Compl. ¶¶ 153-189. The EPPs and GEHA assert a total of ten claims for violations of state antitrust laws, state consumer protection laws, and common law unjust • enrichment. See EPP Compl. ¶¶ 162-205; GEHA Compl. ¶¶ 125-218. II. REGULATORY BACKGROUND The Food and Drug Administration (“FDA”) must approve all new drugs before a company can begin sales in the United States. Hatch-Waxman Act, 21 U.S.C. § 355(a). To obtain FDA approval, the company must file a New Drug Application (“NDA”), which contains information about the safety and efficacy of the drug, the components of the drug, and any patents issued on the composition of the drug or methods for its use. § 355(b)(1). The FDA publishes this information in the directory of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book.” Filing a NDA is a long, expensive, and complicated process. F.T.C. v. Actavis, Inc., - U.S. -, 133 S.Ct. 2223, 2228, 186 L.Ed.2d 343 (2013). Generic drugs offer significant cost-savings, so Congress passed the Hatch-Wax-man Act in order to provide an additional streamlined FDA approval process. DPP Compl. ¶ 44; EPP Compl. ¶ 38; GEHA Compl. ¶ 33; see Pub.L. No. 98-417, 98 Stat. 1585 (1984). Under the Hatch-Wax-man Act, a generic manufacturer can file an Abbreviated New Drug Application (“ANDA”), and show that the generic drug is biologically and pharmaceutically equivalent to an FDA-approved brand-name drug. 21 U.S.C. § 355(j)(2)(A). The generic manufacturer does not need to conduct time-consuming and costly trials anew, but can rely on the scientific findings of safety and effectiveness included in the brand-name drug’s NDA.' Actavis, 133 S.Ct. at 2228. In order to protect the brand-name drug manufacturer’s patent rights, the generic manufacturer must make one of four “paragraph” certifications (i) that no patent for the brand-name drug has been filed with the FDA (paragraph I); (ii) that the patent for the brand-name drug has expired (paragraph II); (iii) that the patent for the brand-name drug will expire on a .particular date and the generic company does not seek to market its generic product before that date (paragraph III); or (iv) that the patent for the brand-name drug is invalid or will not be infringed by the generic manufacturer’s proposed product (paragraph IV). 21 U.S.C. § 355(g)(2)(A)(vn). After filing an ANDA with a paragraph IV certification, the generic manufacturer must send notice to the patent holder. § 355(j)(2)(B). This notice is treated as actual infringement, and triggers a forty-five day period during which the patent holder may file a patent infringement lawsuit before the generic reaches the market. § 355(j)(5)(B)(iii). If the patentee files suit, the FDA stays the ANDA for the lesser of thirty months or entry of final judgment of non-infringement or invalidity. § 355(j)(5)(B)(iii). During this stay, the FDA can grant tentative approval. § 355(j)(5)(B)(iv)(II)(dd). The first party to file a paragraph IV ANDA receives a special benefit, a period of 180 days where the FDA will not grant any competing ANDA. § 355(j)(5)(B)(iv). This exclusivity period can be “worth several hundred million dollars” to the generic drug manufacturer, who typically earns most of the profits on the generic drug during this time. Actavis, 133 S.Ct. at 2229. However, this only excludes other generic manufacturers, not the brand-name drug manufacturer who can always release a generic. § 355(j)(5)(B)(iv)(I). Generic drugs that are released by the brand-name drug manufacturer are called “authorized generics,” and they allow the brand-name drug manufacturer to recover some of the sales and profits it would otherwise lose when an ANDA applicant begins to sell the generic drug. III. FACTUAL BACKGROUND Lidoderm is the brand-name for an adhesive patch that contains the drug lido-caine, which is used to treat pain associated with post-herpetic neuralgia. DPP Compl. ¶ 1; EPP Compl. ¶ 1; GEHA Compl. ¶ 1. In 1998, Hind Health Care, Inc. (“Hind”) developed Lidoderm, submitted an NDA to the FDA, granted Endo an exclusive marketing and distribution license, and transferred full ownership of and responsibility for Lidoderm to Teikoku Seiyaku Co. or its wholly-owned subsidiary Teikoku Pharma USA. DPP Compl. ¶¶ 14, 15, 56, 57; EPP Compl. ¶¶ 64, 65, 67; GEHA Compl. ¶¶55, 56, 58. Lido-derm became a “blockbuster” drug that had no bioequivalent generic version until Watson released one in September 2013. DPP Compl. ¶ 3. Endo’s United States sales revenue for Lidoderm was $825 million in 2011 and $947 million in 2012. DPP Compl. ¶¶ 3,133; GEHA Compl. ¶ 4. A. Endo Protects Lidoderm with Patents and a Citizen Petition Initially, Hind identified two patents in the Lidoderm NDA: U.S. Patent Nos. 5,411,738 (“the '738 patent”) and 5,601,838 (“the '838 patent”). DPP Compl. ¶ 59; EPP Compl. ¶ 67; GEHA Compl. ¶58. Both the '738 and '838 patents (“the Hind Patents”) expired on May, 2, 2012. Id. After acquiring Lidoderm, Teikoku amended the NDA by identifying an additional patent, U.S. Patent No. 5,827,529 (“the '529 patent”), to be listed in the Orange Book for Lidoderm. DPP Compl. ¶¶ 60-64; EPP Compl. ¶¶ 68, 69; GEHA Compl. ¶¶ 59-63. The '529 patent will expire on October 17, 2015. Id. In July, 2008, Endo was sued by LecTek Co. for infringing two patents; U.S. Patent Nos. 5,741,510 (“the '510 patent”) and 5,536,263 (“the '263 patent”). Endo settled this litigation in 2009, paying $23 million in exchange for exclusive licenses to use the '263 and '510 patents. DPP Compl. ¶ 66; EPP Compl. ¶¶ 72-75; GEHA Compl. ¶¶ 64, 65. One year later, Endo granted Teikoku a sublicense to use the '510 patent, who then submitted it for listing in the Orange Book for Lidoderm. DPP Compl. ¶ 68; EPP Compl. ¶ 74; GEHA Compl. ¶ 66. In May, 2011, Endo purchased full title to the '510, '263, and two additional patents from LecTec Co. (“the Rolf Patents”). DPP Compl. ¶¶ 70, 74; EPP Compl. ¶ 76; GEHA Compl. ¶ 69. In addition, Endo filed and maintained an ongoing Citizen Petition with the FDA. In its petition, Endo requested that the FDA require purported generic manufacturers to conduct clinical trials to demonstrate bioequivalence with Lidoderm. Motion to Dismiss (“MTD”) 7 [Dkt. 95] (citing Endo Pharm. Inc., Citizen Petition at 1-2 FDA Dkt. No. 2006P-0522 (Dec, 18, 2006), available at http://www. fda.gov/ohrms/dockets/dockets/06p0522/06 p-0522-cp00001-01-voll.pdf). B. Watson Files an ANDA to Sell a Generic Version of Lidoderm On November 13, 2009, Watson sought to market a generic version of Lidoderm and submitted an ANDA. DPP Compl. ¶¶ 72, 73; EPP Compl. ¶77; GEHA Compl. ¶ 70. Pursuant to a paragraph IV certification, Watson claimed that their generic drug would not infringe the '529 patent, and/or that the '529 patent was invalid and/or unenforceable. DPP Compl. ¶ 71; EPP Compl. ¶ 77; GEHA Compl. ¶71. Watson did not claim noninfringement of the Hind patents, indicating that it would begin marketing generic Lidoderm after those patents expired in May 2012. DPP Compl. ¶ 73; EPP Compl. ¶ 78; GEHA Compl. ¶ 73. Similarly, Watson did not address the Rolf '510 Patent because Tei-koku did not list it in the Orange Book until November, 2010. DPP Compl. ¶ 74; EPP Compl. ¶ 79; GEHA Compl. ¶74. C. Endo Sues Watson for Infringing the '529 Patent Shortly after Watson filed the ANDA, Endo/Teikoku sued Watson for infringing the '529 Patent. Endo Pharm. Inc., et al., v. Watson Labs., Inc. et al., Case No. 10-cv-00138, 2010 WL 722565 (D.Del. Feb. 19, 2010). This triggered the 30-month automatic stay, which was set to expire in mid-July of 2012 or when a final judgment was entered in the litigation. DPP Compl. ¶ 76; EPP Compl. ¶ 81; GEHA Compl. ¶ 76. In June 2011, Endo filed a second suit against Watson. Endo Pharm. Inc. v. Watson Labs., Inc., Case No. 10-cv-00575, 2011 WL 2681992 (D.Del. June 29, 2011). This suit alleged that Watson’s generic Lidoderm would infringe three of the four Rolf patents, specifically, the '510, '333, and '334 Patents, none of which had been listed in the Orange Book when Watson filed the ANDA. DPP Compl. ¶¶ 78, 79; EPP Compl. ¶ 82; GEHA Compl. ¶78. Around the same time, Endo amended its Citizen Petition to request that the FDA require a more complicated method to ensure that a generic was bioequivalent with Lidoderm before approving AND As. EPP Compl. ¶¶ 46-50; GEHA Compl. ¶ 6. In early 2012, Judge Sleet of the District of Delaware conducted a bench trial in the first suit where, plaintiffs allege, “the evidence at trial was overwhelmingly in favor of Watson, exposing the '529 Patent to a determination that it was invalid or unenforceable and that the patent did not cover either the brand[name] product or Watson’s generic product.” DPP Compl. ¶ 79; EPP Compl. ¶ 85; GEHA Compl. ¶ 79. At trial, Watson argued that the '529 Patent was invalid because (i) Teikoku knew of prior art patents that disclosed a “hydro-gel transdermal patch formulation substantially similar to that claimed in the '529 patent,” (DPP Compl. ¶¶ 80, 81); and (ii) the PTO had rejected the '529 patent four times for a variety of reasons. DPP Compl. ¶ 82. Additionally, Watson argued that its generic did not infringe the '529 Patent because Judge Sleet had constructed the patent claims so the patent only covered products- containing “one and only one of the listed alternatives” and Watson’s generic Lidoderm contained three or four of the listed alternatives. DPP Compl. ¶¶ 84-88; EPP Compl. ¶¶ 87-95; GEHA Compl. ¶¶ 80-88. D. Watson and Endo Settle On May 28, 2012 — after the bench trial but before Judge Sleet issued his decision — Watson and Endo/Teikoku settled. DPP Compl. ¶ 93; EPP Compl. ¶ 103; GEHA Compl. ¶ 96. The settlement contained four key terms. First, Watson agreed to delay launching its generic Lido-derm until September 15, 2013; about a year after the FDA’s 30-month stay expired, and about one year before the '510 patent was due to expire and two years before the '529 patent was due to expire. DPP Compl. ¶ 94; EPP Compl. ¶ 104; GEHA Compl. ¶ 97. Second, Endo/Teiko-ku agreed to drop the pending lawsuits and not further amend the Citizen Petition. Third, Endo/Teikoku agreed to give Watson $96 million worth of brand-name Lidoderm patches to distribute or sell, with the condition that Watson honor Endo/Teikoku’s existing price-related contracts. DPP Compl. ¶¶ 95-99; EPP Compl. ¶ 106; GEHA Compl. ¶98. Fourth, Endo/Teikoku agreed not to release their authorized generic Lidoderm until seven and one half months after Watson began selling its generic version. DPP Compl. ¶ 99; EPP Compl. ¶ 111; GEHA Compl. ¶ 102. During this exclusivity period, Watson agreed to pay Endo/Teikoku a twenty-five percent royalty on the Gross Profit for sales of the generic Lidoderm. DPP Compl. ¶¶ 99-105; EPP Compl. ¶ 115; GEHA Compl. ¶ 11. Plaintiffs estimate that this term amounted to a payment of $170 million or more. DPP Compl. ¶¶ 107-115; EPP Compl. ¶ 113; GEHA Compl. ¶ 103. Although the FDA approved Watson’s ANDA on August 23, 2012, Watson did not begin selling generic Lidoderm until September 15, 2013, pursuant to the parties’ agreement. DPP Compl. ¶ 142; EPP Compl. ¶ 80; GEHA Compl. ¶112. Endo/Teikoku was legally allowed to sell its authorized generic Lidoderm at any time; however it waited until May 2014, seven and one half months after Watson began selling its own. DPP Compl. ¶ 104; EPP Compl. ¶ 112; GEHA Compl. ¶ 105. LEGAL STANDARD I. MOTION TO DISMISS A motion to' dismiss is proper under Federal Rule of Civil Procedure 12(b)(6) where the pleadings fail to state a claim upon which relief can be granted. Fed. R. Civ. P. 12(b)(6). A complaint may be dismissed if it does not allege “enough facts to state a claim to relief that is plausible on its face.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007). “A claim has facial plausibility when the pleaded factual content allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009). However, “a complaint [does not] suffice if it tenders naked assertions devoid of further factual enhancement.” Id. (quotation marks and brackets omitted). “Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice.” Id. If a motion to dismiss is granted, a court should normally grant leave to amend unless it determines that the pleading could not possibly be cured by allegations of other facts. Cook, Perkiss & Liehe v. N. Cal. Collection Serv., 911 F.2d 242, 247 (9th Cir.1990). II. SHERMAN ACT § 1: LEGAL STANDARD Section 1 of the Sherman Antitrust Act provides that “[e]very contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal.” 15 U.S.C. § 1. Interpreted literally, this would forbid every contract, so the antitrust laws are primarily applied to agreements that have “genuine adverse effects on competition.” Actavis, 133 S.Ct. at 2234. Before Actavis, circuits were split regarding what test to apply for reverse payment settlement agreements between brand-name and generic drug manufacturers. Some circuits applied the “scope-of-the-patent” test, which dismissed antitrust claims if the anticompetitive effects of the settlement fell “within the scope of the exclusionary potential of the patent.” See, e.g., FTC v. Watson Pharms., 677 F.3d 1298 (11th Cir.2012) cert. granted, - U.S. -, 133 S.Ct. 787, 184 L.Ed.2d 527 (2012) and rev’d and remanded sub nom F.T.C. v. Actavis, Inc., - U.S. -, 133 S.Ct. 2223, 186 L.Ed.2d 343 (2013). Other courts used the “quick look test,” which placed the burden on defendants to show procompetitive benefits of the reverse payment settlement agreement. See, e.g., In re K-Dur Antitrust Litigation, 686 F.3d 197 (3d Cir.2012) cert. granted, - U.S. -, 133 S.Ct. 2849, 180 L.Ed.2d 904 (2013) and vacated and remanded sub nom Upsher-Smith Labs., Inc. v. Louisiana Wholesale Drug Co., - U.S. -, 133 S.Ct. 2849, - L.Ed.2d - (2013). In Actavis, the Court rejected both alternatives and instead chose the “rule of reason” test in order to strike a balance “between the lawful restraint on trade of the patent monopoly and the illegal restraint prohibited broadly by the Sherman Act.” Actavis, 133 S.Ct. at 2231. Under the traditional rule-of-reason test, the plaintiff must prove that there was: (i) an agreement between two or more persons who intend to harm or restrain competition; (ii) an actual injury to competition; and (iii) the harm or restraint is unreasonable as determined by balancing the injury against any justifications or pro-competitive effects of the restraint. California Dental Ass’n v. F.T.C., 224 F.3d 942, 947 (9th Cir.2000). The defendant has the burden to assert any justifications for or pro-competitive effects of the agreement. Id. In Actavis, the Court held that, for a term to raise antitrust concerns: (i) the term must be a “payment”; (ii) the payment must be “reverse”; (iii) the reverse payment must be “large”; and (iv) the large reverse payment must be “unexplained.” Actavis, 133 S.Ct. at 2237. The Supreme Court identified five considerations that support the conclusion that large and unexplained reverse payments violate the Sherman Act. Id. First, such payments have the “potential for genuine adverse effects on competition.” Id. at 2234. The brand-name manufacturer can use them to purchase the exclusive right to sell the patented product, a right it purportedly already possesses. Id. If a generic manufacturer abandons a viable claim in exchange for a portion of the brand-name manufacturer’s monopoly profits, then the brand-name manufacturer is able to retain the monopoly profits that “would otherwise be lost in the competitive market.” Id. at 2235. Without this payment, the generic competitor would enter the market and vigorously compete. The benefits of this lost competition “would flow in large part to consumers in the form of lower prices.” Id. at 2234. The Court noted that this harm to competition does not occur in a “settlement on terms permitting the patent challenger to enter the market before the patent expires.” Id. Second, a payment can be justified if it reflects “a rough approximation of the litigation expenses saved through the settlement” or “compensation for other services that the generic has promised to perform.” Id. at 2235-36. A settlement term that is justified by “traditional settlement considerations” does not harm competition. Id. at 2236. Thus, an “antitrust defendant may show in the antitrust proceeding that legitimate justifications are present.” Id. Third, large payments that potentially “work unjustified anticompetitive harm” independently demonstrate that the paten-tee has the market power to “charge prices higher than the competitive level.” Id. Stated another way, if a brand-name manufacturer does not have the power to charge supracompetitive prices, it is unlikely “to pay large sums to induce others to stay out of its market.” Id. (citations omitted). Fourth, “it is normally not necessary to litigate patent validity to answer the antitrust question,” because an “unexplained large reverse payment itself would normally suggest that the patentee has serious doubts about the patent’s survival.” Id. If the patentee has such doubts, that suggest that the intent behind the payment “is to maintain supracompetitive prices to be shared among the patentee and the challenger rather than face what might have been a competitive market — the very anti-competitive consequence that underlies the claim of antitrust unlawfulness.” Id. “In a word, the size of the unexplained reverse payment can provide a workable surrogate for a patent’s weakness.” Id. at 2236-37. Fifth, the Court reiterated that it was not concerned with all patent infringement settlements. Id. For example, parties may settle by allowing “the generic manufacturer to enter the patentee’s market prior to the patent’s expiration, without the patentee paying the challenger to stay out prior to that point.” Id. at 2237. However, if the basic reason the parties prefer a reverse payment is “a desire to maintain and to share patent-generated monopoly profits, then, in the absence of some other justification, the antitrust laws are likely to forbid the arrangement.” Id. With this guidance, the Supreme Court stated that lower courts should structure the rule of reason analysis “so as to avoid, on the one hand, the use of antitrust theories too abbreviated to permit proper analysis, and, on the other, consideration of every possible fact or theory irrespective of the minimal light it may shed on the basic question — that of the presence of significant unjustified anticom-petitive consequences.” Id. at 2237. Most district courts read Actavis to hold that it is the “large and unjustified reverse payment” that creates the anticompetitive concerns, and only after finding such a payment in the settlement may courts engage in the traditional rule of reason analysis. See, e.g., In re Loestrin 24 Fe Antitrust Litig., Case No. 13-mdl-2472, 45 F.Supp.3d 180, 189, 2014 WL 4368924, at *7 (D.R.I. Sept. 4, 2014) (“Actavis appears to impose a three-part inquiry” where plaintiffs must show a reverse payment, that is large and unjustified, and that violates the rule of reason); see also In re Effexor XR Antitrust Litig., Case No. 11-mdl-5479, 2014 WL 4988410, at *19 (D.N.J Oct. 6, 2014) (the term was not a large and unjustified reverse payment, so the court did not apply the rule of reason); In re Lipitor Antitrust Litig., Case No. 12-cv-02389, 46 F.Supp.3d 523, 546-47, 2014 WL 4543502, at *22 (D.N.J. Sept. 12, 2014) (same). Finally, to demonstrate standing under the Sherman Act, a private plaintiff ■ must prove that he or she suffered damages from the antitrust violation, which requires showing that there is a causal connection between the illegal practice and the private plaintiffs antitrust injury. Rebel Oil Co. v. Atl. Richfield Co., 51 F.3d 1421, 1445 (9th Cir.1995). The Sherman Act’s concern is consumer welfare, therefore “antitrust injury occurs only when the claimed injury flows from acts harmful to consumers.” Id. DISCUSSION I. SHERMAN ACT § 1: REVERSE PAYMENT SETTLEMENT AGREEMENT A. Step One: Was There a Reverse Payment? A reverse payment has the “potential for genuine adverse effects on competition.” Actavis, 133 S.Ct. at 2234. Plaintiffs allege that the settlement contained two terms that were payments for Watson’s agreement not to introduce its generic for until September 15, 2013 (13 months after the FDA approved Watson’s ANDA) (i) Endo/Teikoku’s agreement to give Watson $96 million worth of brand-name product; and (ii) Endo/Teikoku’s agreement not to introduce an authorized generic for seven and one half months; DPP Compl. ¶¶ 95, 99. The parties do not contest that these terms were reverse because they flowed from the patentee (Endo/Teikoku) to the alleged infringer (Watson). Defendants instead argue that these two terms were not payments under Actavis for two reasons: (i) antitrust scrutiny of patent settlements is warranted only when the patent holder pays a generic challenger to stay out of the market, and the settlement here allowed Watson to enter the market more than a year before the expiration of Endo/Teikoku’s patents, (Mot. 16); and (ii) Actavis is limited to cash-only payments. Reply in Support of Joint Motion to Dismiss Plaintiffs’ Complaints (“Reply”) 5 [Dkt. 108]. 1. Is every settlement term that allows early entry protected from antitrust scrutiny? The defendants argue that the two terms are protected from antitrust scrutiny because they allowed Watson to enter the market before it otherwise would have been able to. Mot. 16. As the Supreme Court noted, a patent infringement settlement does not raise antitrust concerns if it allows “the generic manufacturer to enter the patentee’s market prior to the patent’s expiration, without the patentee paying the challenger to stay out prior to that point.” Actavis, 133 S.Ct. at 2234. In other words, while the right to sell a generic drug on the market before a patent expires is valuable, it is not itself a payment because it benefits consumers. Id. Defendants argue that each of the two terms falls within this exception and is not an impermissible payment under Actavis because each allowed Watson to enter the market before the expiration of the '510, '333, '334, and '529 patents, before the patent litigation and appeals were resolved in court, and, for the term that provided brand-name Lidoderm, before the resolution of the ANDA. Mot. 16-18. Defendants’ argument mistakenly distinguishes between early-entry settlements, where the value to the generic manufacturer comes solely from the ability to enter the market with a competing product, and a reverse-payment term, where the value to the generic manufacturer comes from compensation from the patentee. Id. Defendants argue that the Court’s exception includes all terms that allow early-entry because they create competition that benefits customers, while the reverse payments do not. Id. Defendants argue that both terms in the challenged settlement were akin to early-entry settlements because they only provided value to Watson if it entered the market and sold $96 million worth of brand-name Lidoderm and then its own generic Lidoderm. Id. The distinction between early-entry and reverse-payment settlements is not relevant, plaintiffs argue, because it rests on the argument that the two terms are pro-competitive, which is an affirmative defense to an antitrust claim that may not be raised in a motion to dismiss. Plaintiffs’ Consolidated Opposition to Defendants’ Joint Motion to Dismiss (“Oppo.”) 9 [Dkt. No. 103]. Additionally, plaintiffs argue that the Supreme Court only carved out an exception for “one kind of settlement [that] may be free from antitrust scrutiny one consisting solely of an early entry provision.” See In re Lamictal, Case No. 12-cv-995, 18 F.Supp.3d 560, 567, 2014 WL 282755, at *7 (D.N.J. Jan. 24, 2014). Even though some terms that allow early-entry are procompetitive and not subject to antitrust scrutiny as a matter of law, as defendants argue, here plaintiffs plausibly allege that the provision of brand-name product was not procompetitive because it did not “increase output, reduce price, or increase consumer choice.” DPP Compl. ¶ 98. The settlement prohibited Watson from directly competing with Endo because Watson agreed to honor Endo’s price-related contracts. DPP Compl. ¶¶ 95, 98. Moreover, plaintiffs specifically and plausibly allege that Watson in fact sold the brand-name Lidoderm at the same supracompetitive prices as Endo. DPP Compl. ¶ 98. Plaintiffs also allege that the payment had an anticompetitive effect because Watson would have released its generic Lidoderm before September 15, 2013 if Endo/Teikoku had not paid $96 million worth of brand product. DPP Compl. ¶ 142. Defendants rely on Asahi Glass Co. v. Pentech Pharm, Inc., 289 F.Supp.2d 986 (N.D.Ill.2003), for the proposition that an agreement to supply free product to a generic competitor is not a reverse payment because it requires an additional party to enter the market, thus increasing competition. Mot. 17. This case is not persuasive. It was decided ten years before Actavis, and no longer applies current antitrust law. Asahi, 289 F.Supp.2d at 992 (applying the scope-of-the patent test; “there is no doubt that the patent may well be valid, so that Glaxo cannot be faulted for trying to enforce it.”). Moreover, it is factually inapposite here because plaintiffs plausibly allege that Watson’s sales of Lidoderm did not increase competition and were sold at the same supracom-petitive prices. But see id. at 993 (the competitor could use the provided product to undersell the brand manufacturer). Plaintiffs have not cited, and I have not found any case where brand product is used as payment for the delay in a post-Actavis case. But here, plaintiffs have plausibly alleged that this term was not within the category of settlements that the Supreme Court declared was beneficial to consumers and exempt from antitrust scrutiny. With respect to the no-authorized-generic term, plaintiffs plausibly allege that it not only failed to provide a procompetitive benefit, it caused actual harm and is the basis for several claims. See DPP Compl. ¶¶ 160-167; EPP Compl. ¶¶ 171-181; GEHA Compl. ¶¶ 144, 153(b). Plaintiffs assert that the price of a generic drug is 90% of the brand-name’s when there is a single generic manufacturer; however the price drops' to 52% of the brand-name’s when a second generic manufacturer enters the market. DPP Compl. ¶¶ 110(c), 111(a) (citing Generic Competition and ■ Drug Prices, http://www.fda.gov/About FDA/CentersOffices/OfficeofMedical ProductsandTobacco/CDER/ucml29385. htm). If Endo/Teikoku and Watson had concurrently entered the generic market, as they were legally allowed to do as of August 2012, then plaintiffs allege that but for the agreement, an authorized generic version of Lidoderm would have been available on the market simultaneously with the launch of Watson’s generic, and consumers would have paid far less for generic Lidoderm. DPP Compl. ¶¶ 143, 144. On this motion to dismiss, plaintiffs have plausibly pled that the no-authorized-generic and provision of brand-name Lido-derm terms were not beneficial to consumers despite the fact that Watson was allowed to enter the market before patent expiry. Thus they are not akin to the early-entry settlements that Actavis held were not subject to antitrust scrutiny. 2. Are non-monetary terms “payments” in the Actavis framework? Defendants argue that Actavis is “limited to reverse payment settlements in which the branded company pays cash to the generic company.” Reply 5 (emphasis in original). Two district courts have granted motions to dismiss in post-Actavis cases on the grounds that the non-monetary settlement terms are not “payments.” See In re Loestrin, 2014 WL 4368924, at *10 (“Actavis should be applied only to cash settlements, or to their very close analogues.”); see also In re Lamictal, 2014 WL 282755, at *9 (granting motion to dismiss antitrust claims because a reverse payment must be monetary). These cases are not persuasive because both turn on the court’s concern that the value of “a non-cash settlement, particularly one that is multifaceted and complex (like the arrangement here), is almost impossible to measure.” Id. at *9. I agree that in order to determine if a term is a large and unjustified payment, as Actavis requires, courts must be able to calculate its value. See In re Effexor XR, 2014 WL 4988410, at *22. However, not all non-monetary payments are impossible to value. There are many plausible methods by which plaintiffs may calculate the value of non-monetary terms. I agree with the bulk of the recent decisions holding that courts need not restrict the definition of “payments” under Actavis to cash. See, e.g., In re Nexium (Esomeprazole) Antitrust Litig., 968 F.Supp.2d 367, 382 (D.Mass.2013) (rejecting a motion to dismiss because a no-authorized-generic term could be a payment for the delay because a broader definition of payment “serves the purpose of aligning the law with modern-day realities.”). Here, the parties’ own settlement states that the patentee (Endo/Teikoku) shall give the infringer (Watson) “Brand Product of value totaling twelve million dollars ($12,000,000) per month ... on the first business day of each month beginning January 1, 2013 and ending August 1, 2013 (for a total of eight (8) months).” DPP Compl. ¶ 95 (emphasis in original). Watson expected this term to generate close to $96 million from these sales, and plaintiffs allege that it did. Id. at ¶ 98. This term is not a complex, multifaceted payment; rather it is a simple transfer of a fungible product. Calculating its value is straightforward, and plaintiffs have plausibly alleged facts sufficient to support their calculations. Id. This payment is also reverse because it flowed from the patentee to the alleged infringer. DPP Compl. ¶ 97. Endo/Teikoku’s agreement not to release an authorized generic that could compete with Watson during the 180-day exclusivity period is more complex. Defendants categorize this term as a partially exclusive license and argue that it is within the “right to exclude provided by the Patent Act.” Mot. 18. Then, they argue that plaintiffs failed to plausibly allege “an appropriate method of calculating the value of Endo’s agreement not to launch an authorized generic.” Reply to DPP 6. Plaintiffs rebut the argument that the no-authorized-generic agreement was an exclusive license because it was not “one where the patent holder turns over its patent rights to another, [who], having stepped into the shoes of the patent holder, alone practices the patented invention.” Oppo. 17 (citing Barnett v. Strom, 265 F.Supp.2d 946, 949 (N.D.Ill.2003) (“One of the most basic fundamentals of patent law and practice [is that w]hen a patentee has granted an exclusive license, even the pat-entee is prohibited from practicing the art disclosed by the patent.”)). Regardless, they argue, licenses are still subject to antitrust scrutiny, especially when “a licensee [is] agreeing to delay competing with the patentee in exchange for” the license. Id. at 19. I agree with the courts who have held that a no-authorized-generic term can constitute a payment. See In re Niaspan, 2014 WL 4403848, at *11 (“the Court rejects defendants’ argument that a no-AG provision has the same economic effect as the grant of an exclusive license to enter the market prior to the expiration of a patent.”). Defendants have not cited, and I have not found, any cases holding that an agreement not to release an authorized generic cannot be a “payment” under the Actavis framework because it is a partially-exclusive license. If the no-authorized-generic term has any value — which defendants concede it does — then it plausibly incentivized Watson to accept an entry date later than it otherwise would have. This is precisely the harm that Actavis sought to prevent. Plaintiffs estimate the value of the no-authorized-generic agreement by calculating the difference between Watson’s projected revenues with the agreement and Watson’s projected revenues had it competed with Endo/Teikoku’s authorized generic from the start. DPP Compl. ¶ 109. Plaintiffs rely on a study conducted by the FDA to allege that it “is common in the pharmaceutical industry” for the first generic drug entering the market without competition to capture 80% of the brand-name’s, and set the price at 90% of the brand-name’s. DPP Compl. ¶¶ 110, 111 (citing Generic Competition and Drug Prices, http://www.fda.gov/AboutFDA/ CentersOffices/OfficeofMedical ProductsandTobacco/CDER/ucml29385. htm). In contrast, a generic drug entering the market with an authorized generic competitor will only take 40% of the market, and the resulting competition will drive the price down to 52% of the brand-name’s. Id. Applying these percentages to Endo’s publicly available sales information, Watson’s projected revenues for the seven and one half month period would be $278,437,500 with the agreement, but only $107,250,000 without the agreement. DPP Compl. ¶ 112. These calculations are not overly complicated, and they are plausible. B. Step Two: Were the Reverse Payments Large and Unjustified? Defendants argue that the complaints fail to establish that the free brand product and no-authorized-generic payments were large and unjustified because they didn’t plead the value of the litigation costs that were avoided by the settlement of the patent infringement cases. Reply 6. Defendants also allege that plaintiffs do not properly evaluate the no-authorized-generic agreement because they do not account for the 25% royalty that Watson was required to pay Endo for the sales on Watson’s generic during that period of exclusivity. Reply to DPP 6. The latter argument is incorrect, as plaintiffs’ valuations explicitly account for the 25% royalty. DPP Compl. ¶ 107. In Actavis, the Court did not define “large.” At one extreme, a “large” payment could be “a sum even larger than what the generic would gain in profits if it won the paragraph IV litigation and entered the market.” Actavis, 133 S.Ct. at 2235. At the other extreme, perhaps a “large” payment is anything more than the value of the avoided litigation costs plus any other services provided from the generic to the brand manufacturer. See In re Effexor XR., 2014 WL 4988410, at *23. The Supreme Court gave more guidance for “unjustified,” holding that a payment is justified when it reflects “traditional settlement considerations, such as avoided litigation costs or fair value for services.” Actavis, 133 S.Ct. at 2236. Such terms do not raise the “concern that a patentee is using its monopoly profits to avoid the risk of patent invalidation or a finding of noninfringement.” Id. The burden is on the defendant to “show in the antitrust proceeding that legitimate justifications are present, thereby explaining the presence of the challenged term and showing the lawfulness of that term under the rule of reason.” Actavis, 133 S.Ct. at 2236. Here, Plaintiffs do not provide an estimate of. the avoided litigation costs; instead they argue that the payments at issue are so large — $266 million — that they have “no rational connection to, and far exceed, any approximation of the costs of continuing the patent litigation.” DPP Compl. ¶¶ 117, 117. Because this is a motion to dismiss, defendants are unable to show that their expected litigation costs or other services justified the alleged value of the terms. However, given the status of the underlying patent litigation — the first case was tried and submitted for a bench decision and the second case had proceeded past the pleading stage — the plaintiffs’ allegations that the payments were large and unjustified are plausible. C. Step Three: Rule of Reason The defendants argue that the settlement does not pass the rule of reason test because it was procompetitive as a matter of law, essentially rehashing their initial arguments that I rejected above. Mot. 7. Additionally, they contend that the outcome of the litigation and Watson’s ANDA was far from certain when Watson and Endo/Teikoku entered into the settlement. Id. They allege that the settlement allowed Watson to enter the market earlier than it would have if defendants had not settled because the pending litigation and regulatory obstacles, including the pending Citizen Petition, were too great to suggest otherwise. Id. They conclude that liability cannot be established without proof that the alleged payment caused Watson’s generic to enter later than it would have absent the payment. Id. As discussed above, I have found that plaintiffs have plausibly pled the existence of large and unjustified reverse payments. As the Court stated, “the size of the unexplained reverse payment can provide a workable surrogate for a patent’s weakness, all without forcing the court to conduct a detailed exploration of the validity of the patent itself.” Actavis, 133 S.Ct. at 2236-37. Here, Endo/Teikoku was willing to give Watson $96 million worth of brand product, abstain from selling an authorized generic for seven and one half months, while sacrificing more than one to two years of patent protection in order to resolve the lawsuits and delay the entry of Watson’s generic until September 15, 2013. On this record — and taking plaintiffs’ plausible factual assertions as true — plaintiffs have alleged that the outcome of the patent litigation was reasonably certain to favor Watson. The size of the payments supports these allegations. I do not need to analyze the validity of the patents in the settled litigation in order to find the allegations adequate to meet the rule of reason. Plaintiffs have plausibly alleged that the settlement was an agreement between two or more persons who intended to harm or restrain competition; that the agreement caused an actual injury to competition; and that the injury was unreasonable. D. Step Four: Did the Settlement Cause Antitrust Injury? Defendants argue that Watson would not have been able to enter the market before September 15, 2013, therefore the settlement did not cause an antitrust injury. Mot. 21. Plaintiffs respond with two theories of injury (i) Watson was able and willing to launch “at-risk” (as soon as it obtained FDA approval, but before the patent litigation was finally resolved); and (ii) the settlement would have allowed generic Lidoderm to enter the market even earlier if Endo/Teikoku had not purchased a delay with the two payments. DPP Compl. ¶ 122 Plaintiffs assert that Watson would have been able to launch at-risk as soon as it received FDA approval, which occurred on August 23, 2012. DPP Compl. ¶ 75, EPP Compl. ¶ 80, GEHA Compl. ¶ 75. At oral argument, defendants countered that this entry date is speculative, because the settlement affected the FDA’s decision to deny Endo’s Citizen Petition and approve Watson’s ANDA. Defendants’ argument relies on matters outside of the pleadings — namely what the FDA’s practice is when a patentee with a pending Citizen Petition settles with a generic manufacturer who has a pending ANDA. On a motion to dismiss, the Court reviews only plausible allegations in the complaints and matters subject to judicial notice. Plaintiffs’ assertion that Watson was able to enter the market on August 23, 2012 after it received FDA approval is plausible. To demonstrate Watson’s willingness to enter the market at-risk, both parties cite to comments that Watson representatives made during an earning call. Oppo. 23, Mot. 23. Plaintiffs note that Watson was planning to launch at “the earliest possible time.” DPP Compl. ¶ 124. Defendants dispute plaintiffs’ characterization of the Watson earnings calls, and argue that Watson was not willing to launch at-risk because they expressed concern about the ongoing Citizen Petition. See Mot. at 23 (citing RJN Ex. D at 7 “there is still the Citizen Petition overhang, which sits out there and of course, we’re waiting for a trial decision. But we are doing everything we can to be ready to go at the earliest possible time.”). Defendants also rely on In re Nexiwn, a case where the generic manufacturer moved for summary judgment, and offered unrebut-ted evidence “that an at risk launch was ‘unlikely’ and ‘extremely risky.’ ” In re Nexium (Esomeprazole) Antitrust Litig., Case No. 12-mdl-02409, 42 F.Supp.3d 231, 272, 2014 WL 4370333, at *33 (D.Mass. Sept. 4, 2014). This, however, is a motion to dismiss and defendants cite to no comparable evidence that is properly before the Court at this juncture. Whether a generic manufacturer is willing to risk treble damages from a patent infringement suit by selling a generic drug at risk is a generally a factual issue.' In re Lipitor, 2013 WL 4780496, at *24. Here, Watson representatives stated in the Q3 2011 earnings call that it believed that the patents were invalid. RJN Ex. 7 (“We like our case, we like where our case sits. We think we’ve, the District Court has been certainly in the Markman hearing was, we think was favorable to us and we’re pretty excited about where that product opportunity presents itself.”); RJN Ex C. 16 (“There’s a possibility that the judge would rule from the bench or shortly thereafter.”). Also supporting the position that Watson was willing to launch at-risk is the fact that Watson had increased production capacity and procured the raw materials in preparation for a launch in 2012. DPP Compl. ¶ 124. Finally, the size of the payment Watson was able to obtain from Endo/Teikoku (over $200 million) also demonstrates Endo/Teikoku’s fear that Watson would have cleared the regulatory hurdles and launched its generic before September 15, 2013. See Actavis, 133 S.Ct. at 2236. The allegations that Watson was expanding its facilities, preparing for an imminent launch, and stating that it was confident about both its chances of success on the patent litigation are plausible and support plaintiffs’ theory of at-risk entry. As an alternative theory of injury, plaintiffs allege that Endo/Teikoku used the two payments to purchase part or all of Watson’s 13 month delay (from August 2012 through September 2013). DPP Compl. ¶ 118. Thus, if the parties had entered into a hypothetical settlement without payments for the delay, plaintiffs would have paid less for Lidoderm because generic Lidoderm would have entered the market before September 15, 2013. Plaintiffs argue that this theory of injury was ratified by Actavis, which held that a “payment in return for staying out of the market — simply keeps prices at the patentee-set levels, potentially producing the full patent-related $500 million monopoly return while dividing that return between the challenged patentee and the patent challenger. The patentee and the challenger gain; the consumer loses.” Actavis, 133 S.Ct. at 2234-35. Defendants argue that this theory of injury “is tantamount to a preference for a different settlement, one that provided for even earlier entry.” Mot. 19 (citing Verizon Commc’ns Inc. v. Law Offices of Curtis v. Trinko, 540 U.S. 398, 415-16, 124 S.Ct. 872, 157 L.Ed.2d 823 (2004)). In Actavis, the Supreme Court held that settlements with large unjustified reverse payments can violate the Sherman Act, even though the settlement allowed some early-entry. Actavis, 133 S.Ct. at 2237. A settlement that only allows early-entry does not harm consumers; however a settlement that allows early entry in conjunction large and unjustified reverse payments can. Id. (parties may “settle in other ways, for example, by allowing the generic manufacturer to enter the paten-tee’s market prior to the patent’s expiration without the patentee paying the challenger to stay out prior to that point.”) As discussed above, plaintiffs have plausibly alleged that the terms were large and unjustified reverse payments, which is sufficient to support plaintiffs’ theories of injury at this juncture. Defendants have not demonstrated procompetitive effects sufficient to offset the alleged injury to competition under the rule of reason analysis. Defendants’ motion to dismiss the Section 1 claims is DENIED. II. SHERMAN ACT § 1: PER SE TREATMENT OF THE NO-AUTHORIZED-GENERIC Plaintiffs also argue that the no-authorized-generic term is an independent agreement not to compete that is per se illegal under Section 1. Oppo. 19. Defendants respond that the agreement is not per se illegal because it is not a naked agreement not to compete, and therefore must be evaluated under the rule of reason standard. Reply 10. The per se standard was created to streamline antitrust claims in situations where the agreement has “such a predictable and pernicious anticompetitive effect, and such limited potential for procompeti-tive benefit” that courts may predict with confidence that the conduct is unreasonably anticompetitive every time it arises. Northern Pacific Ry. Co. v. United States, 356 U.S. 1, 5, 78 S.Ct. 514, 2 L.Ed.2d 545 (1958); see also Broad. Music, Inc. v. Columbia Broad. Sys., Inc., 441 U.S. 1, 19-20, 99 S.Ct. 1551, 60 L.Ed.2d 1 (1979). Until Actavis, courts held that “the right to license [a] patent, exclusively or otherwise, or to refuse to license at all, is ‘the untrammeled right’ of the patentee.” Westinghouse Elec. Corp., 648 F.2d at 647. Actavis fundamentally altered the landscape and directed district courts to apply the rule of reason analysis to patent settlements. Actavis, 133 S.Ct. at 2237. Plaintiffs have not cited, and I have not found, any case where a no-authorized generic agreement was analyzed under the per se test. Instead, district courts have considered no-authorized generic agreements under the rule of reason approach as set forth by the Court in Actavis and discussed above. The motion to dismiss the per se Section 1 claim is GRANTED. III. SHERMAN ACT §2 A. Legal standard Section 2 of the Sherman Antitrust Act provides that “[e]very person who shall monopolize, or attempt to monopolize, or combine or conspire with any other person or persons, to monopolize any part of the trade or commerce among the several States, or with foreign nations, shall be deemed guilty of a felony.” 15 U.S.C. § 2. A claim of monopoly has two elements: (i) monopoly power; and (ii) unlawful acts. United States v. Grinnell Corp., 384 U.S. 563, 571, 86 S.Ct. 1698, 16 L.Ed.2d 778 (1966). A plaintiff alleging attempted monopoly under Section 2 must demonstrate four elements: (i) specific intent to control prices or destroy competition; (ii) predatory or anticompetitive conduct directed at accomplishing that purpose; (iii) a dangerous probability of achieving “monopoly power”; and (iv) causal antitrust injury. Rebel Oil Co., 51 F.3d at 1433. Similarly, a plaintiff alleging a conspiracy to monopolize in violation of Section 2 must show four elements: (i) the existence of a combination or conspiracy to monopolize; (ii) an overt act in furtherance of the conspiracy; (iii) the specific intent to monopolize; and (iv) causal antitrust injury. Paladin Associates, Inc. v. Montana Power Co., 328 F.3d 1145, 1158 (9th Cir.2003). B. Shared Monopoly Defendants argue that all three Section 2 claims fail because, as a matter of law, they require plaintiffs to plead that a single entity possesses monopoly power. Mot. 24. The complaints refer to “Endo/Teikoku,” and do not allege that either Endo or Teikoku individually possessed, threatened to possess, or conspired to possess monopoly power. Id. Plaintiffs respond that Endo and Teikoku acted as a single economic entity that monopolized the market for lidocaine patch 5%, and therefore should be treated as a single entity under Section 2. Oppo. 25. Alternatively, they request that I treat the complaints as if they had alleged that Endo alone possessed monopoly power. Oppo. 27. Finally, they request that I grant them leave to amend their complaints. Plaintiffs do not cite any case where a court held a manufacturer and its distributor jointly liable for violating Section 2. A monopoly, by definition, consists of a single firm, and both monopolization and attempted monopolization are single-firm violations. See Rebel, 51 F.3d at 1443 (holding that “[t]o pose a threat to monopolization, one firm alone must have the power to control market output and exclude competition.”); see also, Terminalift LLC v. International Longshore and Warehouse Union Local 29, Case No. 11-cv-1999, 2013 WL 2154793, at *3 (S.D.Cal.2013) (“The very phrase ‘shared monopoly’ is paradoxical.”). Here, the complaints do not distinguish whether Endo or Teiko-ku possessed monopoly power. Plaintiffs could have alleged that either party possessed market power because, for example, Teikoku owned the '529 patent for Lido-derm, while Endo owned the '510 patent. DPP Compl. ¶¶ 58, 67. In some situations, two companies can “pool their capital and share the risks of loss as well as the opportunities for profit ... such joint ventures [are] regarded as a single firm competing with other sellers in the market.” Texaco, Inc. v. Dagher, 547 U.S. 1, 6, 126 S.Ct. 1276, 164 L.Ed.2d 1 (2006). However such joint ventures typically involve the creation of a new integrated company that is run by representatives from both companies. Id. Plaintiffs cite no authority where an exclusive distribution agreement, like the one between Endo and Teikoku, has sufficed to establish a joint venture and liability for a monopolization claim. The most analogous case is In re Well-bwtrin XL Antitrust Litigation, where the plaintiffs brought a monopoly claim against the producers and distributors of a brand-name drug. Case No. 08-mdl-2431, 2009 WL 678631, at *6-8 (E.D.Pa. Mar. 13, 2009). In that case, the distributor licensed the drug from the producer, and while the producer profited as a “recipient of royalties on [the distributor]’s profits ... [it] did not participate in the U.S. market directly.” Id. at *7-8. The court dismissed the claims against the producer and allowed the monopolization claims to proceed against the distributor because the complaint specifically alleged that the distributor alone “was able to maintain 100% control of the U.S. market for” the drug. Id. at *7. Here a monopolization or attempted monopolization claim cannot stand against both Endo and Teikoku. Plaintiffs allege that Endo markets and sells Lidoderm in the United States, while Teikoku manufacturers Lidoderm in Japan. DPP Compl. ¶¶ 13-14. However, unlike Wellbutrin XL, plaintiffs do not allege that either Endo or Teikoku individually has market power in the United States over Lidoderm, instead referring to Endo/Teikoku. See, e.g., DPP Compl. ¶ 130141. Defendants argue that the conspiracy to monopolize claim must fail for the same reason, as the conspiracy must “allege specific intent by Defendants to empower one of them with monopoly power.” Standfacts Credit Servs., 405 F.Supp.2d at 1152. Again, the complaints do not allege that the parties conspired to endow either Endo or Teikoku with market power. It is plausible that plaintiffs could allege either that Endo possessed market power within the United States, as it was the sole distributor of Lidoderm in the United States, or that Teikoku possessed market power within the United States because it controlled the production and the primary patents. DPP Compl. ¶ 57. Plaintiffs may also be able to allege specifically that Endo and Teikoku conspired to give one or the other monopoly power, but those allegations are missing from the existing complaints. The motion to dismiss the three monopoly claims is GRANTED with LEAVE TO AMEND. IV. STATE LAW CLAIMS Defendants move to dismiss the state law claims asserted by GEHA and the EPPs arguing first that because the federal law claims of the DPPs fail, so must the derivative claims of GEHA and the other EPPs. However, as discussed above, I find that the federal claims — except for the per se claim under Section 1 and the monopolization claims — have been adequately-pleaded and survive. With respect to the state law claims for monopolization, I find the allegations in the EPP and GEHA complaints are no different than those in the DPP complaint that have been dismissed with leave to amend. Therefore, the EPP and GEHA claims regarding monopoly are likewise DISMISSED with leave to amend. I will address the defendants’ remaining challenges to the state law claims in turn. A. Article III Standing Defendants argue that the claims of GEHA and the EPPs arising under the common law of each state must be dismissed because the plaintiffs fail to plead adequate factual allegations to establish their standing to assert each state’s laws. At its core, defendants’ argument is that GEHA cannot bring claims under any law other than Missouri — where it resides— and the EPPs can bring claims under only the laws of the eight states where an EPP resides. As discussed below, I agree the issue should be resolved at this juncture, reject defendants unduly narrow concept of standing, find that GEHA has alleged standing only for its claims under Missouri law, and agree that the EPPs fail to allege sufficient facts to support standing for specific states where no EPP was injured. 1. Whether Standing to Pursue State Law Claim Claims Should be Decided Now Standing is a “necessary element of federal-court jurisdiction under Article III” and a “threshold question in every federal case.” Thomas v. Mundell, 572 F.3d 756, 760 (9th Cir.2009) (citing Worth v. Seldin, 422 U.S. 490, 498, 95 S.Ct. 2197, 45 L.Ed.2d 343 (1975)). Defendants contend that in order to have Article III standing, plaintiffs must allege that they were injured in a particular state in order to bring claims under that state’s laws. Numerous district court cases, many arising under state antitrust laws, have agreed. See, e.g., Los Gatos Mercantile, Inc v. E.I. DuPont De Nemours & Co., Case No. 13-1180 BLF, 2014 WL 4774611, at *4 (N.D.Cal. Sept. 22, 2014) (dismissing indirect purchaser claims for states where no named plaintiff purchased or was injured by a product, because “ ‘[i]f a complaint includes multiple claims, at least one named class representative must have Article III standing to raise each claim.’ ” (quoting 5 J. Moore et al., Moore’s Federal Practice § 26.63[1][b] at 23-304 (3rd Ed. 2014)); Pardini v. Unilever United States, Inc., 961 F.Supp.2d 1048, 1061 (N.D.Cal.2013) (granting motion to dismiss state law claims based on laws of states where no named plaintiff resided or was injured); In re Optical Disk Drive Antitrust Litig., Case No. 10-2143 RS, 2011 WL 3894376, at *13 (N.D.Cal. Aug. 3, 2011) (“Defendants have adequately shown that dismissal of state law claims is appropriate with respect to those jurisdictions in which none of the named class representatives reside, notwithstanding plaintiffs’ arguments that it would not contravene standing requirements to allow those claims to proceed.”); In re Flash Memory Antitrust Litig., 643 F.Supp.2d 1133, 1164 (N.D.Cal.2009) (“Where, as here, a representative plaintiff is lacking for a particular state, all claims based on that state’s laws are subject to dismissal.”); In re Apple & AT & TM Antitrust Litig., 596 F.Supp.2d 1288, 1309 (N.D.Cal.2008) (same); In re Ditropan XL Antitrust Litig., 529 F.Supp.2d 1098, 1107 (N.D.Cal.2007) (dismissing for lack of standing claims based on the antitrust law of the states where no named plaintiff was injured); In re Graphics Processing Units Antitrust Litig., 527 F.Supp.2d 1011, 1026 (N.D.Cal.2007) (dismissing state-law anti